Saturday, Sept 5, 2009
The document on the WHO website linked below states that it is common procedure to release pandemic viruses into the population in order to get a jump ahead of the real pandemic, so as to fast track the vaccine for when it is needed.
In Europe, some manufacturers have conducted advance studies using a so-called “mock-up” vaccine. Mock-up vaccines contain an active ingredient for an influenza virus that has not circulated recently in human populations and thus mimics the novelty of a pandemic virus.
According to the website, “Such advance studies can greatly expedite regulatory approval.”
Dr. Mercola’s Comments:
On June 11 the World Health Organization (WHO) raised its swine flu pandemic alert from a 5 to a 6. Phase 6 is the highest level alert, and reflects the speed with which a virus is spreading — not its severity.
This classification also allows for a vaccine to qualify for a “fast-track” procedure for licensing and approval, and this process is now ongoing for the swine flu vaccine.
What you may not know, however, is that WHO, together with health officials, regulatory authorities and vaccine manufacturers, have been working since 2007 – long before this new “threat” of swine flu emerged – to “explore a broad range of issues surrounding the regulatory approval of pandemic vaccines.”
According to the WHO website:
“Ways were sought to shorten the time between the emergence of a pandemic virus and the availability of safe and effective vaccines.”
One such method used in Europe is to conduct advance studies using a “mock-up” vaccine that contains an active ingredient for an influenza virus that has not circulated recently in human populations.
When testing these mock-up vaccines, it is very possible to release the novel influenza virus into the population, as its purpose is to “mimic the novelty of a pandemic virus” and “greatly expedite regulatory approval.”
This article was posted: Saturday, September 5, 2009 at 3:31 am